- Conditions
- Heart Failure, Cardiomyopathy, Dilated
- Interventions
- AccuCinch® Ventricular Restoration
- Device
- Lead sponsor
- Ancora Heart, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 18
- States / cities
- San Francisco, California • Atlanta, Georgia • Louisville, Kentucky + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 134
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Endothelial Dysfunction, LVAD
- Interventions
- Exposure of interest - Use of left ventricular assist device (LVAD)
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Heart Failure NYHA Class III
- Interventions
- BaroStim
- Device
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Riverhead, New York
- Conditions
- Heart Failure
- Interventions
- LCZ696 (sacubitril/valsartan)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 794 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 66 more
- Conditions
- Heart Failure, Reduced Ejection Fraction
- Interventions
- sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 23
- States / cities
- Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more
- Conditions
- Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy
- Interventions
- MYK-491, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 9
- States / cities
- Jacksonville, Florida • Saint Paul, Minnesota • St Louis, Missouri + 6 more
- Conditions
- Heart Failure
- Interventions
- Splanchnic nerve block, Sham-control procedure
- Device · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Heart Failure
- Interventions
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 18
- States / cities
- Fountain Valley, California • Wilmington, Delaware • Fort Lauderdale, Florida + 15 more
- Conditions
- Aging, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Frailty, Physical Function, Quality of Life
- Interventions
- Inspiratory Muscle Training (IMT), Standard of Care
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Best Practice Alert
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type2diabetes, Heart Failure With Reduced Ejection Fraction
- Interventions
- Empagliflozin 25 MG Oral Tablet, Placebo, Acipimox 250 Mg Oral Capsule
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- LY3461767, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • St Louis, Missouri • Chapel Hill, North Carolina
- Conditions
- Hypertension, Pulmonary, Heart Failure With Reduced Ejection Fraction
- Interventions
- Eko CORE 500 Digital Stethoscope
- Device
- Lead sponsor
- Eko Devices, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,850 participants
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- O'Fallon, Illinois • Springfield, Illinois • Norfolk, Virginia
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Interventions
- Tovinontrine (CRD-750), Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 23 more
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Interventions
- XXB750, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Inverness, Florida • Jacksonville, Florida • Saint Paul, Minnesota
- Conditions
- Heart Failure With Reduced Ejection Fraction, Pulmonary Hypertension, Right Heart Failure Due to Left Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
- Interventions
- SRD-001, Placebo
- Biological · Drug
- Lead sponsor
- Sardocor Corp.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 5
- States / cities
- San Diego, California • San Francisco, California • St Louis, Missouri + 2 more
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Extra-virgin olive oil
- Other
- Lead sponsor
- Old Dominion University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- DeltaG (250 mg/kg), DeltaG (500 mg/kg)
- Dietary Supplement
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Powerbreathe
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- Vericiguat (BAY1021189) 5 mg
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 5
- States / cities
- Alexander City, Alabama • Richmond, Indiana • Baltimore, Maryland + 2 more
- Conditions
- Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99,209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- LCZ696
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,980 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • Muscle Shoals, Alabama • Little Rock, Arkansas + 20 more